Neuphoria Therapeutics Inc.Neuphoria Therapeutics Inc.Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc.

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪9.57 M‬USD
−11.32USD
‪−10.15 M‬USD
0.00USD
Beta (1Y)
4.81
Employees (FY)
24
Change (1Y)
−1 −4.00%
Revenue / Employee (1Y)
0.00USD
Net income / Employee (1Y)
‪−422.99 K‬USD

About Neuphoria Therapeutics Inc.


CEO
Spyridon Papapetropoulos
Headquarters
Eastwood
Founded
1996
FIGI
BBG01RFZ8658
Bionomics Limited engages in the discovery and development of therapeutics for cancer and diseases of the central nervous system in Australia. It has small molecule product development programs in the areas of cancer, anxiety, epilepsy, and multiple sclerosis. The company develops its lead cancer compound, BNC 105, for the treatment of solid tumors, such as breast, lung, colon, and prostate cancers. BNC 105 is a member of the class of compounds, known as vascular disruption agents or VDAs, which shut down the blood supply within a tumor, starving the tumor and preventing its continued growth. The company has commercial partnerships with Genmab A/S; Athena Diagnostics; Laboratory Corporation of America; and Genetic Technologies, Ltd. Bionomics Limited was founded in 1999 and is based in Thebarton, Australia.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Neuphoria Therapeutics Inc. stocks are traded under the ticker NEUP.
NEUP stock has fallen by −35.00% compared to the previous week, the month change is a −35.00% fall, over the last year Neuphoria Therapeutics Inc. has showed a −35.00% decrease.
NEUP stock is 180.00% volatile and has beta coefficient of 4.81. Track Neuphoria Therapeutics Inc. stock price on the chart and check out the list of the most volatile stocks — is Neuphoria Therapeutics Inc. there?
Yes, you can track Neuphoria Therapeutics Inc. financials in yearly and quarterly reports right on TradingView.
Neuphoria Therapeutics Inc. is going to release the next earnings report on Feb 20, 2025. Keep track of upcoming events with our Earnings Calendar.
No, NEUP doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 26, 2024, the company has 24.00 employees. See our rating of the largest employees — is Neuphoria Therapeutics Inc. on this list?
Like other stocks, NEUP shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Neuphoria Therapeutics Inc. stock right from TradingView charts — choose your broker and connect to your account.